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We have previously shown that antisense oligo-
nucleotides effectively reduced insulin-like growth
factor I receptor expression in human psoriatic skin
grafted on to nude mice when injected intradermally.
We therefore investigated the penetration of C-5 pro-
pyne modi®ed antisense oligonucleotides into human
normal and psoriatic skin after topical administration.
Oligonucleotide (37.5 mg; 250 mM) was applied in
aqueous solution or 5% methylcellulose gel for 24 h,
prior to live confocal microscopy and ¯uorescence
microscopy of ®xed sections. We found that oligo-
nucleotide could penetrate through the stratum cor-
neum of psoriatic but not normal human skin over
large regions of the epidermis. The oligonucleotide
was localized to the nucleus of large parakeratotic
cells in the psoriatic skin as well as smaller basal and
suprabasal keratinocytes. In normal human skin,
oligonucleotide was con®ned to the stratum corneum,
with little or no oligonucleotide apparent in the
viable epidermis. Electrophoresis of oligonucleotide
recovered from treated psoriatic and normal skin
revealed that the oligonucleotide remained intact over
the 24 h period. In summary, we found that C-5 pro-
pyne modi®ed antisense oligonucleotides could reach
the target cells (in this case basal keratinocytes) after
topical administration to psoriatic but not normal
skin. Key words: antisense oligonucleotide/psoriasis/topical
delivery. J Invest Dermatol 118:1003±1007, 2002
A
nti-sense oligonucleotides are increasingly being
considered as therapeutic options for a range of
disease states, particularly as the development of
second generation oligonucleotides have reduced
concerns regarding toxicity. We have recently shown
that antisense oligonucleotides targeting the insulin-like growth
factor-I receptor could be used to normalize the psoriatic epidermis
after repeated intradermal injection into grafted human skin
(Wraight et al, 2000). A desired feature of any cutaneous therapy
is a user-friendly topical formulation, and thus further investigation
of the ability of these agents to be effective, topically-applied drugs
is warranted.
The use of antisense oligonucleotides in dermatology has been
the subject of considerable interest due to the attractiveness of the
concept of antisense therapy and the ease of access to the target
organ for these large, charged therapeutic agents. The stratum
corneum, however, is well equipped to prevent the access of large
charged substances due to its physical, chemical, and enzymatic
barrier properties. We have previously found that oligonucleotide
does not penetrate normal human skin grafts on athymic mice to a
signi®cant degree (White et al, 1999). When grafts were tape
stripped, however, there was extensive nuclear localization of
oligonucleotide throughout the epidermis, indicating that the
stratum corneum does act as a signi®cant barrier to oligonucleotide
delivery across the skin.
A number of studies have demonstrated antisense penetration
and or ef®cacy using different methods to overcome the skin
barrier. These methods included intradermal injection (White et al,
1999; Wraight et al, 2000), iontophoresis (Vlassov et al, 1994;
Oldenburg et al, 1995; Regnier and Preat, 1998), and electropor-
ation (Regnier and Preat, 1998). None of these methods, however,
are currently well suited to use in the delivery of therapeutic agents
due to considerations of cost or discomfort.
One skin condition known to involve impaired differentiation of
keratinocytes and reduced stratum corneum barrier function is the
common autoimmune disease psoriasis. The reduction in barrier
function is attributed to a number of characteristics of psoriatic skin
that are a result of the impairment of corneocyte differentiation,
including impaired formation and secretion of lamellar body
contents and processing of lamellar body contents into lamellar
bilayers (Ghadially et al, 1996). Conditions in which there is an
impaired ability to prevent oligonucleotide penetration may
therefore be far more amenable to antisense therapy than those in
which the barrier function remains intact.
The aim of this study was therefore to compare the penetration
of oligonucleotides in human psoriatic skin with that in normal
human skin. We found that oligonucleotide penetration in psoriasis
is indeed markedly greater than that in normal skin, apparently
involving the entry of oligonucleotide through areas of severe
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barrier function impairment followed by lateral oligonucleotide
spread throughout the viable epidermis.
MATERIALS AND METHODS
Ex vivo maintenance of normal and psoriatic skin biopsies Psoriatic
skin was obtained from volunteers under protocol 94012A of the Royal
Children's Hospital Ethics in Human Research Committee. Two 8 mm
punch biopsies were obtained from affected areas on the abdomen.
Normal human skin was obtained from discards of plastic surgery. The
method of skin maintenance for 24 h was adapted from that of Russo
et al (1994). Speci®cally, on receipt of psoriatic or normal skin,
subcutaneous tissue was removed and the skin was placed on a stainless
steel mesh coated in 2% agar, with the dermis in contact with the agar.
The agar was itself in contact with Dulbecco's modi®ed Eagle's medium
(Gibco BRL, Melbourne, Australia) with 10% fetal bovine serum. A
reservoir containing phosphate-buffered saline (PBS) surrounded the
culture medium reservoir, providing humidity.
Application of ¯uorescein isothiocyanate (FITC)-oligonucleo-
tide A total of 14 normal skin samples and 13 psoriatic skin samples
were used in the study. Six normal skin samples and six psoriatic skin
samples received 37.5 mg (250 mM) FITC-R451 in PBS. The aqueous
applications involved 3 3 10 ml applications over a period of 2 h, and
imaging was performed at 24 h. Alternatively, six normal and ®ve
psoriatic samples received 10±37.5 mg FITC-oligonucleotide in 5%
methylcellulose gel in a single application, with the nature of the gel
imposing some variability on the ®nal dose applied. Finally, two normal
and two psoriatic samples received an alternative oligonucleotide, FITC-
DT1064, in PBS as above.
Live confocal microscopy (LCM) LCM of skin samples was
performed as previously described (White et al, 1999). The samples were
imaged 24 h after oligonucleotide application for all samples. Imaging
was performed using an Optiscan f900e laser scanning confocal
microscope (Optiscan Ltd, Melbourne, Australia) equipped with an
argon ion laser providing 488 nm (blue) excitation and with ¯uorescence
detection above 515 nm (green). For each sample, a series of horizontal
sections were taken at increasing depths into the epidermis. Pilot
experiments demonstrated that ¯uorescence could be detected up to
100 mm below the skin surface.
Assessment of oligonucleotide penetration in ®xed sections of
human skin After live confocal imaging, the skin was ®xed in 4%
paraformaldehyde for 24 h followed by 24±72 h in 0.5 M sucrose. The
samples were then embedded in paraf®n wax, and 5 mm sections were
cut and mounted on silanized slides. Sections were dewaxed in histolene,
rehydrated in graded ethanols, rinsed, and mounted with Mowiol
(Calbiochem, Clayton, Victoria, Australia) with DABCO anti-fade
(Sigma, St Louis, MO).
Analysis of oligonucleotide stability The treated skin samples were
homogenized with a Kinematica PT 1200 Polytron in 20 mM Tris±HCl
pH 8.0; 150 mM NaCl; 10% glycerol buffer containing 1% Triton X-
100, and centrifuged at 20,000 3 g for 10 min at 4°C. The pellet was
resuspended in distilled water containing 1 mg per ml proteinase K and
incubated for 1 h at 56°C. Formamide (25 ml) was added and the sample
heated to 55°C for 5 min The samples were analyzed on a 19%
polyacrylamide 90 mM Tris borate, 20 mM ethylenediamine tetraacetic
acid gel, containing 7 M urea and transferred on to a Zeta-Probe
membrane (Bio-Rad, Sydney, Australia). The membrane was blocked
with 10 mM Tris±HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20
containing 5% skim milk powder for 1 h at room temperature, then
incubated with alkaline phosphatase-conjugated anti-¯uorescein immuno-
globulin (Vistra ECF Western blotting kit; Amersham, Buckinghamshire,
U.K.); 1:2500 dilution for 1 h at room temperature. Bands were
visualized by chemi¯uorescence.
Oligonucleotides Two different-3¢-FITC-conjugated C-5 propynyl
dC dU phosphorothioate oligonucleotide 15mers were used, with the
following sequences: R451ÐUAACACGAUACGCGA; DT1064Ð
CACAGUUGCUGCAAG.
RESULTS
FITC-oligonucleotide penetrates the stratum corneum of
human psoriatic skin after topical administration in PBS or
5% methylcellulose gel LCM Imaging of skin treated with
FITC-R451 as described in Materials and Methods showed clear
penetration of the oligonucleotide into subsurface keratinocytes
over the entire surface of the skin when in aqueous solution
(Fig 1A±C) or in 5% methylcellulose gel (Fig 1D±F). Figure 1
shows oligonucleotide localized in large (10±15 mm diameter)
parakeratotic cells at the surface of the skin (Fig 1A) or
orthokeratotic cells just below the surface of the skin (Fig 1D,
optical section 5 mm below the surface), which were nucleated and
very thin as determined by optical sectioning. As imaging
continued deeper into the skin, smaller oligonucleotide-
containing nuclei were apparent, with the smallest cells observed
to contain nuclei characterized in a previous study to be basal/
suprabasal (» 5 mm diameter; White et al, 1999). Figures 1(B, C)
and (E, F) show images obtained from optical sections 18±60 mm
below the surface of the skin after treatment with oligonucleotide
in PBS or methylcellulose gel, respectively, showing keratinocyte
nuclei had taken up oligonucleotide at this depth.
Figure 1. FITC-oligonucleotide (R451) pene-
trates the stratum corneum in ex vivo human
psoriatic skin. Affected psoriatic skin was
removed by punch biopsy and maintained ex vivo
as described in Materials and Methods. FITC-R451
was added to biopsies for 24 h at 37°C prior to
LCM. (A±C) FITC-R451 (37.5 mg; 250 mM) in
PBS; (D±F) FITC-R451 (37.5 mg; 250 mM) in
5% methylcellulose gel. Nucleus indicated in (A)
11.7 mm, image depth = 0; nucleus indicated in
(B) 6.4 mm, image depth = 18 mm; nucleus
indicated in (C) 5.5 mm, image depth = 56 mm;
(D) image depth = 5 mm; nucleus indicated in (E)
9.5 mm, image depth = 29 mm; nucleus indicated
in (F)5.3 mm, image depth = 60 mm. Field of
view: 100 mm.
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Fluorescence microscopy of FITC-oligonucleotide
distribution Topical oligonucleotide-treated psoriatic skin
samples were also imaged using ¯uorescent microscopy after
®xation and sectioning. Figure 2 shows representative
¯uorescence imaging of sections treated with FITC-R451 in PBS
(Fig 2A) or 5% methylcellulose (Fig 2B). Oligonucleotide
appeared to penetrate to the basal epidermis over a wide area of
the biopsy for each of the donors. Arrows in Fig 2(A) show
apparent points of entry through the stratum corneum, from which
the oligonucleotide may have gained access to a wide area of the
epidermis.
The pattern of widespread distribution and nuclear localization
was consistent with minor variability across the biopsies from the
different patients. Also, an alternative FITC-labeled oligonucleo-
tide (DT1064) exhibited similar distribution characteristics to the
oligonucleotide used for the majority of the experiments (R451).
FITC-oligonucleotide does not penetrate the stratum
corneum of normal human skin after topical adminis-
tration in 5% methylcellulose gel or PBS Both LCM and
¯uorescence microscopy of ®xed sections demonstrated that
oligonucleotide does not penetrate through the stratum corneum
of normal skin samples. Figure 3(A, B) show LCM images of skin
that received FITC-R451 in 5% methylcellulose and PBS,
respectively. Consistent images of ®elds of large squamous cells
were obtained from all normal skin samples imaged after topical
application. The diameter (often 20±30 mm), lack of thickness
(often < 10 mm) of the cells and the lack of apparent nuclei were
indicative of fully differentiated stratum corneum acting as a barrier
for the oligonucleotide. Optical sections taken deeper into the
epidermis revealed no ¯uorescence (data not shown), indicating a
lack of penetration of the oligonucleotide into normal skin. This
was con®rmed by ¯uorescence microscopy of ®xed sections of the
samples imaged using LCM. Figure 3(C) shows a ¯uorescence
microscopy image of oligonucleotide appearing at the surface of the
epidermis and not any deeper into the skin. This was consistent for
each of the samples examined and was con®rmed by immuno-
histochemical analysis of the FITC-oligonucleotide location (data
not shown).
Figure 3(D) shows an image of normal human skin not treated
with oligonucleotide, demonstrating that no auto¯uorescence was
detected using the same confocal settings as images in Figs 3(A, B).
FITC-oligonucleotide remains intact after topical adminis-
tration in both normal and psoriatic human skin There was
no apparent degradation of the oligonucleotide after topical
application for either normal or psoriatic skin. Figure 4 shows a
western immunoblot of homogenized samples of psoriatic skin
from four individual donors treated with FITC-R451 in 5%
Figure 3. LCM and ¯uorescence microscopy of ®xed sections
demonstrate that oligonucleotide does not penetrate the stratum
corneum of normal human skin. Normal human skin was maintained
ex vivo as described in Materials and Methods. FITC-R451 was added to
biopsies for 24 h at 37°C prior to LCM and ®nally ¯uorescence imaging
of ®xed sections. (A, B) LCM of FITC-R451 (37.5 mg; 250 mM) in 5%
methylcellulose gel; (B) FITC-R451 (37.5 mg; 250 mM) in PBS; (C)
¯uorescence microscopy of FITC-R451 (37.5 mg; 250 mM) in 5%
methylcellulose gel (arrow indicates stratum corneum); (D) image of
control (no FITC-oligonucleotide) confocal image of normal human
skin. Scale bars: (A, B) 20 mm; (C, D) 100 mm.
Figure 2. Fluorescence microscopy of ®xed
sections con®rms that FITC-oligonucleotide
(R451) penetrates the stratum corneum in ex
vivo human psoriatic skin. Affected psoriatic
skin was removed by punch biopsy and
maintained ex vivo as described in Materials and
Methods. FITC-R451 was added to biopsies for
24 h at 37°C prior to ®xation (4% paraform-
aldehyde), embedding and sectioning. (A) FITC-
R451 (37.5 mg; 250 mM) in PBS; (B) FITC-R451
(37.5 mg; 250 mM) in 5% methylcellulose gel; (C)
control no FITC-oligonucleotide sections for
¯uorescence. Scale bars: (A, B) 100 mm; (C)
50 mm.
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methylcellulose. Analysis of oligonucleotide size was performed as
described in Materials and Methods. Each of the samples appeared to
contain full length (15mer) oligonucleotide as evidenced by a single
band that appears at the same position as the 15mer control sample.
DISCUSSION
The results of this study indicate that oligonucleotide in aqueous
solution or methylcellulose gel can penetrate the stratum corneum
of psoriatic skin maintained ex vivo from a range of individual
donors. LCM indicated that oligonucleotide can be detected in the
nuclei of small, undifferentiated keratinocytes, over the entire area
of application of the oligonucleotide. The pattern of uptake was
similar in skin receiving oligonucleotide in aqueous solution or
methylcellulose gel, although brighter ¯uorescence was detected in
the skin that received oligonucleotide in aqueous solution.
Fluorescence imaging of ®xed sections con®rmed the LCM ®nding
that oligonucleotide does penetrate throughout the epidermis.
Signi®cantly, local areas of severely impaired stratum corneum
formation appeared to allow extensive oligonucleotide entry to the
basal epidermis, from which lateral spread of the oligonucleotide
appeared to occur. Oligonucleotide did not appear to penetrate
through regions of the stratum corneum that are relatively intact
and properly formed. These ®ndings were not dependent on
oligonucleotide sequence, as an alternative FITC-labeled oligo-
nucleotide exhibited similar distribution characteristics to the
oligonucleotide used for the majority of the experiments. Normal
skin maintained in the same ex vivo apparatus demonstrated its
ability to prevent the penetration of oligonucleotide through the
stratum corneum. No ¯uorescence was found below the stratum
corneum in 14 skin samples maintained ex vivo with oligonucleo-
tide in aqueous solution or methylcellulose. The lack of penetration
of oligonucleotide across normal stratum corneum was in agree-
ment with the ®ndings of Butler et al (1997) but in contrast to those
of Wingens et al (1999) and Mehta et al (2000). Wingens et al (1999)
used chimeric oligonucleotides that could have different pharmaco-
kinetic properties to those oligonucleotides used in this study.
Mehta and colleagues found that phosphorothioate oligonucleotide
could cross the stratum corneum of human skin grafts after
application of a 2% oligonucleotide cream. The variance in results
could be as a result of the oligonucleotide dose (we used » 1/20th
of the oligonucleotide dose of that used by Mehta et al, 2000) or
varying limits of detection. The problem with the use of large
amounts of oligonucleotide is the increased likelihood of
nonsequence-speci®c effects of the oligonucleotide. It was found
previously that repeated intradermal injection of 2.5 mg oligo-
nucleotide produced a reliable antisense effect but also a small
nonsequence-speci®c effect (Wraight et al, 2000. The use of greater
oligonucleotide dose may allow for some penetration of oligonu-
cleotide into the viable epidermis of human skin, but may result in
signi®cant nonsequence-speci®c antisense effects. In any case, at the
doses used in this study, oligonucleotide was found to penetrate the
stratum corneum of psoriatic human skin and not normal human
skin.
The oligonucleotide used in this study was intact after topical
delivery to both normal and psoriatic human skin. A clear single
band was apparent after electrophoresis of the recovered oligo-
nucleotide, and the band was at the same position as a 15mer
control sample. This result is somewhat surprising as oligonucleo-
tide systemically delivered is quickly broken down by nucleases
(Crooke et al, 1996) and the epidermis has a large amount of
enzymatic activity. These results are, however, consistent with
those of Vlassov et al (1994), who found intact oligonucleotide in
mouse tumors after topical administration.
C-5 propyne-modi®ed oligonucleotides were used in this study.
These modi®ed oligonucleotides were selected because their
increased af®nity for target mRNA allows inhibition with lower
concentrations (Wagner et al, 1993) and shorter oligonucleotide
length (Flanagan et al, 1996) than unmodi®ed phosphorothioates,
theoretically reducing the incidence of aptameric effects on target
cells. One of the aims of this study was to deliver these
oligonucleotides topically into psoriatic skin, and therefore the
same chemical modi®cations were used in this study.
The results of this study indicate that oligonucleotides can be
topically applied to psoriatic skin in simple topical formulations and
ef®ciently reach the basal epidermis fully intact. This suggests that
antisense therapy is particularly suited to the treatment of psoriasis
and that complex topical formulations may not be required. The
issue of penetration of oligonucleotide in normal skin is somewhat
more complex. This study indicates that phosphorothioate
oligonucleotide does not penetrate a wide range of normal
human skin samples to any signi®cant degree.
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